Zainabadi K, Walsh KFrances, Vilbrun SCharles, Mathurin LDaniel, Lee MHee, Saito K, Mishra S, Ocheretina O, Pape JWilliam, Nathan C et al..
2021.
Characterization of Differentially Detectable Mycobacterium tuberculosis in the Sputum of Subjects with Drug-Sensitive or Drug-Resistant Tuberculosis before and after Two Months of Therapy.. Antimicrob Agents Chemother. 65(8):e0060821.
Pandey S, Singh A, Yang G, d'Andrea FB, Jiang X, Hartman TE, Mosior JW, Bourland R, Gold B, Roberts J et al..
2021.
Characterization of Phosphopantetheinyl Hydrolase from Mycobacterium tuberculosis.. Microbiol Spectr. 9(2):e0092821.
Zhan W, Zhang H, Ginn J, Leung A, Liu YJ, Michino M, Toita A, Okamoto R, Wong T-T, Imaeda T et al..
2021.
Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Anti-malaria Activity in Humanized Mice.. Angew Chem Int Ed Engl. 60(17):9279-9283.
Zhang H, Hsu H-C, Kahne SC, Hara R, Zhan W, Jiang X, Burns-Huang K, Ouellette T, Imaeda T, Okamoto R et al..
2021.
Macrocyclic Peptides that Selectively Inhibit the Mycobacterium tuberculosis Proteasome.. J Med Chem. 64(9):6262-6272.
Zhang H, Hsu H-C, Kahne SC, Hara R, Zhan W, Jiang X, Burns-Huang K, Ouellette T, Imaeda T, Okamoto R et al..
2021.
Macrocyclic Peptides that Selectively Inhibit the Mycobacterium tuberculosis Proteasome.. J Med Chem. 64(9):6262-6272.
Ray PC, Huggett M, Turner PA, Taylor M, Cleghorn LAT, Early J, Kumar A, Bonnett SA, Flint L, Joerss D et al..
2021.
Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth.. ACS Omega. 6(3):2284-2311.
Aldridge BB, Barros-Aguirre D, Barry CE, Bates RH, Berthel SJ, Boshoff HI, Chibale K, Chu X-J, Cooper CB, Dartois V et al..
2021.
The Tuberculosis Drug Accelerator at year 10: what have we learned? Nat Med. 27(8):1333-1337.